Evidence map›Paper›PMID 38298720›Full record

ArticleHeliyon2024

Laccase-based catalytic microreactor for BPA biotransformation.

Juan Eduardo Sosa-Hernández, Elsa M Gutierrez, Jhosseph S Ochoa Sierra, Osvaldo Aquines, Felipe Robledo-Padilla, Elda M Melchor-Martínez, Hafiz M N Iqbal, Roberto Parra-Salvídar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Juan Eduardo Sosa-HernándezTecnologico de Monterrey, School of Engineering and Sciences, Monterrey, 64849, Mexico.
Elsa M GutierrezDepartmento de Ingeniería Biomédica, Universidad de Monterrey, Monterrey, Nuevo León, Mexico.
Jhosseph S Ochoa SierraEscuela de Microbiología, Universidad de Antioquia, Medellín, Antioquia, Colombia.
Osvaldo AquinesDepartment of Physics and Mathematics, Universidad de Monterrey, San Pedro Garza García, Mexico.
Felipe Robledo-PadillaDepartment of Physics and Mathematics, Universidad de Monterrey, San Pedro Garza García, Mexico.
Elda M Melchor-MartínezTecnologico de Monterrey, School of Engineering and Sciences, Monterrey, 64849, Mexico.
Hafiz M N IqbalTecnologico de Monterrey, School of Engineering and Sciences, Monterrey, 64849, Mexico.
Roberto Parra-SalvídarTecnologico de Monterrey, School of Engineering and Sciences, Monterrey, 64849, Mexico.
Tecnológico de Monterrey · MXUniversity of Monterrey · MXUniversidad de Antioquia · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A laccase-based catalytic reactor was developed into a polydimethylsiloxane (PDMS) microfluidic device, allowing the degradation of different concentrations of the emergent pollutant, Bisphenol-A (BPA), at a rate similar to free enzyme. Among the immobilizing agents used, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) was capable of immobilizing a more significant amount of the laccase enzyme in comparison to glutaraldehyde (GA), and the passive method (2989, 1537, and 1905 U/mL, respectively). The immobilized enzyme inside the microfluidic device could degrade 55 ppm of BPA at a reaction rate of 0.5309 U/mL*min with a contaminant initial concentration of 100 ppm at room temperature. In conclusion, the design of a microfluidic device and the immobilization of the laccase enzyme successfully allowed a high capacity of BPA degradation.

Indexed as

Biocatalytic reactorBisphenol aImmobilizationLaccaseMicrofluidic device

Identifiers

PMID38298720
PMCPMC10827767
OpenAlexW4390755067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.